These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Prevention of Glucocorticoid-Induced Osteoporosis: Clinical audit to evaluate the implementation of National Osteoporosis Guideline Group 2017 guidelines in a primary care setting. Carter M J Clin Densitom; 2019; 22(1):25-30. PubMed ID: 29729949 [TBL] [Abstract][Full Text] [Related]
43. Uncertainties in the prevention and treatment of glucocorticoid-induced osteoporosis. Hansen KE; Wilson HA; Zapalowski C; Fink HA; Minisola S; Adler RA J Bone Miner Res; 2011 Sep; 26(9):1989-96. PubMed ID: 21721042 [TBL] [Abstract][Full Text] [Related]
44. Management of patients on chronic glucocorticoid therapy: an endocrine perspective. Trence DL Prim Care; 2003 Sep; 30(3):593-605. PubMed ID: 14692203 [TBL] [Abstract][Full Text] [Related]
51. An observational study of glucocorticoid-induced osteoporosis prophylaxis in a national cohort of male veterans with rheumatoid arthritis. Caplan L; Hines AE; Williams E; Prochazka AV; Saag KG; Cunningham F; Hutt E Osteoporos Int; 2011 Jan; 22(1):305-15. PubMed ID: 20358362 [TBL] [Abstract][Full Text] [Related]
52. [Randomized controlled trials for the prevention and treatment of glucocorticoid-induced osteoporosis]. Suzuki Y Clin Calcium; 2006 Nov; 16(11):1834-42. PubMed ID: 17079850 [TBL] [Abstract][Full Text] [Related]
54. Prevention and treatment of glucocorticoid-induced osteoporosis. Doga M; Mazziotti G; Bonadonna S; Patelli I; Bilezikian JP; Canalis E; Giustina A J Endocrinol Invest; 2008 Jul; 31(7 Suppl):53-8. PubMed ID: 18791353 [TBL] [Abstract][Full Text] [Related]
55. Prevalence of evaluation and treatment of glucocorticoid-induced osteoporosis in men. Cruse LM; Valeriano J; Vasey FB; Carter JD J Clin Rheumatol; 2006 Oct; 12(5):221-5. PubMed ID: 17023807 [TBL] [Abstract][Full Text] [Related]
56. Prevention of glucocorticoid-induced osteoporosis: experience in a managed care setting. Yood RA; Harrold LR; Fish L; Cernieux J; Emani S; Conboy E; Gurwitz JH Arch Intern Med; 2001 May; 161(10):1322-7. PubMed ID: 11371261 [TBL] [Abstract][Full Text] [Related]
57. Iatrogenic osteoporosis in dermatology. Foo CW; Yukumoto E; DeJournett R; Johnson DW Int J Dermatol; 2009 Oct; 48(10):1035-42; quiz 1042-3. PubMed ID: 19775397 [No Abstract] [Full Text] [Related]
58. Clinical practice guidelines for healthy eating for the prevention and treatment of metabolic and endocrine diseases in adults: cosponsored by the American Association of Clinical Endocrinologists/the American College of Endocrinology and the Obesity Society: executive summary. ; ; Gonzalez-Campoy JM; St Jeor ST; Castorino K; Ebrahim A; Hurley D; Jovanovic L; Mechanick JI; Petak SM; Yu YH; Harris KA; Kris-Etherton P; Kushner R; Molini-Blandford M; Nguyen QT; Plodkowski R; Sarwer DB; Thomas KT; Endocr Pract; 2013; 19(5):875-87. PubMed ID: 24121263 [No Abstract] [Full Text] [Related]
59. Alphacalcidol in prevention of glucocorticoid-induced osteoporosis. Reginster JY; de Froidmont C; Lecart MP; Sarlet N; Defraigne JO Calcif Tissue Int; 1999 Oct; 65(4):328-31. PubMed ID: 10485986 [TBL] [Abstract][Full Text] [Related]
60. Prevention and treatment of glucocorticoid-induced osteoporosis. Curtis JR; Saag KG Curr Osteoporos Rep; 2007 Mar; 5(1):14-21. PubMed ID: 17320023 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]